News

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients
Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.
Capricor falls after report on AdCom meeting cancellation (update)
Capricor Therapeutics (NASDAQ:CAPR) plunged 32% following a trading halt on Friday after Stat News reported that the new head ...
Stocktwits on MSN1d
Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data
Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the ...
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow ...
Capricor Therapeutics' Becker Muscular Dystrophy Drug Gets Orphan Drug Designation in U.S.
Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s ...
Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement
Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...
Investing.com Australia10d
Capricor Therapeutics stock falls after FDA inspection of manufacturing facility
Investing.com -- Capricor Therapeutics Inc (NASDAQ: CAPR) stock tumbled 10.5% after the company announced that the FDA’s inspection of its San Diego manufacturing facility resulted in a Form 483 with ...
FierceBiotech1mon
Capricor shares turn red as FDA plans deramiocel adcomm, likely the first under new commissioner
Capricor Therapeutics saw its shares fall 13% by the end of trading Monday as its investigational cell therapy deramiocel for DMD was revealed as the first drug expected to face an FDA advisory ...
Finanznachrichten1mon
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
In addition, if Capricor were to receive FDA marketing approval for deramiocel regarding the treatment of DMD, Capricor would be eligible to receive a Priority Review Voucher (PRV) based on its ...